Aug 31,2021

Healthcare Industry Leaders Unite Around Patient Safety at Glytec’s Inaugural Conference on Glycemic Innovation and Collaboration

Glytec, the only provider of cloud-based insulin management software across the continuum of care, today revealed details about its inaugural conference on glycemic innovation and collaboration, “Time to Target: Uniting Around Patient Safety.” This event will provide attendees with guidance on the recently announced CMS Core Measures pertaining to glycemic management quality metrics, detailed steps to create and manage a best-in-class glycemic management program at their hospital and examples of real-world strategies to drive and implement clinical change. There is no cost to register for the conference, which will be held virtually on October 26-27, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 30,2021

Rimidi Announces Official Launch of Patient Reported Outcomes Tool, Survé

Rimidi, a leading clinical management platform designed to optimize clinical workflows, today announced the official launch of its EHR-integrated Patient Reported Outcomes (PROs) tool, Survé by Rimidi. The tool delivers questionnaires directly to patients on their device in real-time or in an appointment-driven or data-driven context, working within the existing EHR and layering on configurable clinical decision support.

PRODUCT

#virtual care

View Analyst & Ambassador Comments
Go to original news
Sep 14,2021

Leon Medical Centers Partners with Health Tech Company Rimidi, Reducing A1Cs in High-Risk Cohort of Patients with Type 2 Diabetes

Leon Medical Centers today announced clinical improvements in a cohort of high-risk patients with Type 2 Diabetes due to the remote patient monitoring and clinical decision support capabilities of Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives. Leon began using the Rimidi platform, which integrates directly with their Epic electronic health record (EHR), at the beginning of 2020. 

COLLABORATION PARTNERSHIP

#institution

#rpm

#bgm

View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

What’s the Next Big Breakthrough in Healthcare? Virta Convenes 20+ Industry Leaders to Explore Bold Solutions to Our Most Daunting Challenges

Virta Health’s two-day Moonshots for Health conference—launching Wednesday, September 8—brings together dozens of industry leaders to discuss big ideas for reversing America’s chronic disease epidemic and improving healthcare across the globe.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study

The utility of HbA1c (glycosylated hemoglobin) to estimate glycemic control in populations of African and other low-resource countries has been questioned because of high prevalence of other medical conditions that may affect its reliability. Using continuous glucose monitoring (CGM), we aimed to determine the comparative performance of HbA1c, fasting plasma glucose (FPG) (within 5 hours of a meal) and random non-fasting glucose (RPG) in assessing glycemic burden.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Nemaura Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Loughborough, England – September 1, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Two-year use of flash glucose monitoring is associated with sustained improvement of glycemic control and quality of life (FLARE-NL-6)

The FreeStyle Libre (FSL) is a flash glucose monitoring (FGM) system. The Flash Monitor Register in the Netherlands (FLARE-NL-4) study previously demonstrated the positive effects of FSL-FGM use during 1 year on glycemic control, quality of life and disease burden among persons with diabetes mellitus (DM). The present follow-up study assesses the effects of FSL-FGM after 2 years.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 02,2021

Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of €8.70 per share

Voluntis, a leader in digital therapeutics, and its reference shareholders (Bpifrance Participations, LBO France Gestion, Debiopharm Innovation Fund, SHAM Innovation Santé, Vesalius Biocapital and Indigo) announced today that following the signature of a share purchase agreement with AptarGroup, Inc. on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, Aptar has completed the acquisition of a majority stake in Voluntis from the company’s reference shareholders and certain members of the management, representing approximately 64.6% of the share capital of Voluntis (on a non-diluted basis), at a price of €8.70 per share.

COLLABORATION MERGERS & ACQUISITION

#product & service

#dtx

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 04,2021

Post-Market Surveillance of a Blood Glucose Test Strip Demonstrates No Evidence of Interference on Clinical Accuracy in a Large Cohort of People with Type 1 or Type 2 Diabetes

Regulations and industry guidance relating to testing for interference in blood glucose monitoring (BGM) systems continue to focus on in vitro laboratory bench tests. Post-market surveillance (PMS) in a clinical setting allows for BGM accuracy assessments to evaluate the impact of real-world exposure to polypharmacy in people with diabetes. This study evaluated the OneTouch Select Plus® BGM test-strip accuracy with respect to polypharmacy using a clinical registry dataset.

CLINICAL STUDY

#bgm

View Analyst & Ambassador Comments
Go to original news
Sep 06,2021

Methods for Insulin Bolus Adjustment Based on the Continuous Glucose Monitoring Trend Arrows in Type 1 Diabetes: Performance and Safety Assessment in an In Silico Clinical Trial

The use of continuous glucose monitoring (CGM) sensors in type 1 diabetes (T1D) therapy has spread considerably in the last decade thanks to their improved accuracy,1 the demonstrated beneficial impact on patients’ glycemic control,2-4 and the approval for nonadjunctive use that made them a key element in T1D therapy decision-making process.5,6 The advantages offered by the adoption of CGM devices in T1D therapy are remarkable, since they provide not only quasi-continuous readings of glucose, but also display a trend arrow indicating its magnitude and direction, that is, rate-of-change (ROC). Trend arrows grant a rough short-term forecast of future glucose concentration to the user, who could leverage on them to preventively take hypotreatments or correction insulin boluses to mitigate the upcoming hypoglycemic or hyperglycemic episodes, respectively.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES